GlaxoSmithKline plc (GSK) Given a GBX 1,834 Price Target at Sanford C. Bernstein
GlaxoSmithKline plc (LON:GSK) has been given a GBX 1,834 ($22.35) target price by stock analysts at Sanford C. Bernstein in a research report issued on Wednesday. The brokerage currently has a a “neutral” rating on the stock. Sanford C. Bernstein’s target price indicates a potential upside of 10.02% from the company’s current price.
GSK has been the subject of several other research reports. Goldman Sachs Group Inc. set a GBX 1,800 ($21.94) price objective on shares of GlaxoSmithKline plc and gave the company a “buy” rating in a research note on Wednesday. JPMorgan Chase & Co. reissued a “neutral” rating and issued a GBX 1,667 ($20.32) price objective on shares of GlaxoSmithKline plc in a research note on Wednesday. Bryan, Garnier & Co reissued a “buy” rating on shares of GlaxoSmithKline plc in a research note on Monday. Jefferies Group raised their price objective on shares of GlaxoSmithKline plc from GBX 1,900 ($23.16) to GBX 1,950 ($23.77) and gave the company a “buy” rating in a research note on Thursday, October 13th. Finally, Deutsche Bank AG reissued a “hold” rating and issued a GBX 1,870 ($22.79) price objective on shares of GlaxoSmithKline plc in a research note on Wednesday, October 12th. Three equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and eight have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of GBX 1,680.71 ($20.48).
GlaxoSmithKline plc (LON:GSK) traded down 0.37% during midday trading on Wednesday, hitting GBX 1660.76. 2,358,034 shares of the stock traded hands. GlaxoSmithKline plc has a 12-month low of GBX 1,277.25 and a 12-month high of GBX 1,745.56. The firm’s market cap is GBX 80.73 billion. The company’s 50-day moving average is GBX 1,651.49 and its 200 day moving average is GBX 1,567.94.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/19/glaxosmithkline-plc-gsk-given-a-gbx-1834-price-target-at-sanford-c-bernstein.html
The business also recently announced a dividend, which was paid on Thursday, October 13th. Shareholders of record on Thursday, August 11th were given a dividend of GBX 19 ($0.23) per share. The ex-dividend date of this dividend was Thursday, August 11th. This represents a dividend yield of 1.12%.
In related news, insider Slaoui,Moncef bought 28 shares of the firm’s stock in a transaction on Friday, August 12th. The shares were bought at an average cost of GBX 2,208 ($26.91) per share, for a total transaction of £618.24 ($753.49). Also, insider Witty,Sir Andrew P sold 10,000 shares of the business’s stock in a transaction on Wednesday, July 27th. The stock was sold at an average price of GBX 1,693 ($20.63), for a total transaction of £169,300 ($206,337.60).
About GlaxoSmithKline plc
GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.